RETRACTED: Cosentyx alleviates psoriasis‐induced podocyte injury by inhibiting the tlr/nf‐κb signaling pathway

AbstractBackgroundPathological studies have shown an association between psoriasis and renal podocyte injury, and the specific mechanism of podocyte injury in psoriasis remains unclear, with no effective treatments currently available. This study aimed to investigate the underlying mechanisms of podocyte and epidermal cell injury in psoriasis and evaluate the therapeutic effect of Cosentyx.Materials and methodsA psoriasis‐like mouse model was established using BALB/C mice, and Cosentyx treatment was administered via intraperitoneal injection. Various parameters, including skin lesions, urinary protein, kidney/serum inflammatory cytokines, kidney function, podocyte membrane proteins, and Toll‐like receptors/nuclear factor kappa‐b (TLR/NF‐κB) pathway‐associated proteins, were analyzed to explore the mechanisms of podocyte and epidermal cell injury in psoriasis and the potential ameliorative effects of Cosentyx.ResultTreatment with Cosentyx significantly reduced the increased levels of urinary protein, creatinine, and blood urea nitrogen caused by psoriasis. Cosentyx inhibited the upregulation of kidney/serum inflammatory factors (IL‐17, IL‐1β, IL‐6, TNF‐α, and IL‐22) and TLR/NF‐κB‐related proteins (TLR2, TLR4, MyD88, and NF‐κBp65) in both psoriatic skin and kidney tissues, while also reducing the accumulation of oxidative products. Moreover, Cosentyx treatment suppressed podocyte apoptosis and promoted epidermal cell apoptosis. The experimental data demonstrated that psoriasis‐like inflammation impaired renal podocytes through the TLR/NF‐κB signaling pathway.ConclusionCosentyx treatment effectively inhibited the expression of TLR/NF‐κB‐related proteins, providing a therapeutic effect for psoriasis‐induced kidney and skin injuries.